Drug and Therapeutics Bulletin 1997;35:11-12; doi:10.1136/dtb.1997.35211
Copyright © 1997 by the BMJ Publishing Group Ltd.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation

Rilazole for amyotrophic lateral sclerosis

Relevant BNF section: 4.9.3

Around one in 20,000 adults in the UK will develop amyotrophic lateral sclerosis, the commonest variant of motor neurone disease. Riluzole ({blacktriangledown}Rilutek - Rhône-Poulenc Rorer) was launched in the UK in August 1996 as "the first anti-excitotoxic agent proven to extend life in amyotrophic lateral sclerosis". We review the clinical data on the effectiveness of riluzole and assess its place in the management of amyotrophic lateral sclerosis, a condition that is invariably fatal and has a median survival time from symptom onset of about 2.5 years.1






About DTB - Privacy policy - Terms and conditions relating to subscriptions purchased online - Web site terms and conditions - Feedback

© 1997 BMJ Publishing Group Ltd.